Glossary

The biologically active component within a drug product responsible for its intended therapeutic effect.

A Contract Development and Manufacturing Organization specializing in the complete lifecycle of Active Pharmaceutical Ingredients, from process development and clinical supply to commercial manufacturing.

Testing   performed under extreme storage conditions (e.g., high temperature and humidity) to forecast long-term stability and establish a preliminary shelf-life for a drug substance more quickly.

The principle of assuming full responsibility for project outcomes, adhering to defined quality, timeline, and regulatory requirements outlined in a service agreement.

The capability to quickly and efficiently adapt to changing project demands, including shifts in production scale, synthetic routes, or regulatory feedback. This adaptability is a core operational value at BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO.

The process of designing, validating, and implementing robust analytical methods to measure the identity, purity, potency, and overall quality of an Active Pharmaceutical Ingredient throughout its development lifecycle.

A formal, documented process verifying that a laboratory instrument is correctly installed, operates as intended, and is suitable for its specific purpose, ensuring data accuracy and integrity.

The formal, documented procedure for moving a validated analytical method from one laboratory to another to ensure its continued accuracy and reliability.

The application of various scientific techniques in a quality control environment to measure the physical and chemical characteristics of a substance against its predetermined specifications.

A submission to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of a previously approved branded drug. This application relies on the safety and efficacy findings of the original drug.

The regulatory authority in France responsible for evaluating the safety, efficacy, and quality of medicines and health products.

The national health surveillance agency serving as the primary regulatory body for pharmaceuticals and other health products in Brazil.

Undesirable chemical substances that emerge during the synthesis or storage of an Active Pharmaceutical Ingredient and must be controlled to meet regulatory standards.

The preparation and submission of the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package for an API to health authorities for review and approval.

An early-phase development activity involving the investigation of multiple synthetic pathways to identify the most efficient, scalable, and economically viable route for manufacturing a new Active Pharmaceutical Ingredient.

The process of creating an Active Pharmaceutical Ingredient through a controlled sequence of chemical reactions.

A systematic, annual evaluation of a product's manufacturing process, mandated by cGMP, to verify process consistency, monitor quality trends, and identify improvement opportunities.

The extent to which a substance can dissolve in water. This is a critical physicochemical property influencing a drug's bioavailability and formulation strategy.

A manufacturing technique performed under sterile conditions to produce substances that cannot be terminally sterilized, thereby preventing microbial contamination.

A confidential document submitted directly to regulatory authorities containing detailed, proprietary information about the manufacturing process of an Active Pharmaceutical Ingredient.

An advanced chemical synthesis technique used to selectively produce a specific stereoisomer (enantiomer) of a chiral molecule.

A comprehensive cGMP document providing a detailed and traceable history of the production of a single batch of material.

A contract partner specializing in the development and manufacturing of Active Pharmaceutical Ingredients derived from biological processes.

A chemical reaction where one or more bromine atoms are incorporated into a molecule. This can occur through electrophilic aromatic substitution, addition reactions across double or triple bonds, or radical reactions. Brominated compounds are widely used in various applications, including pharmaceuticals, flame retardants, and agricultural chemicals, and can serve as valuable synthetic intermediates.

It refers to the fraction of a drug that successfully reaches the bloodstream and is available to produce its intended therapeutic effect. The physical properties of an API can be engineered to optimize this.

The use of natural catalysts, such as enzymes, to perform chemical transformations, often resulting in highly selective, efficient, and sustainable manufacturing processes.

The breakdown of materials by microorganisms (e.g., bacteria and fungi), relevant to waste management and environmental impact studies.

A state achieved when two drug products demonstrate a comparable rate and extent of absorption, indicating they will have a similar therapeutic effect.

An enclosed, ventilated laboratory workspace designed to protect the user, the product, and the environment from hazardous biological materials.

A therapeutic product, such as a protein or antibody, manufactured in, extracted from, or semi-synthesized from biological sources.

A specialized, controlled apparatus used to cultivate microorganisms or cells that produce a desired biologic API.

It’s a type of biological medicine that closely resembles an already approved reference product, with no significant differences in safety, effectiveness, or how it works in the body.Its approval pathway relies on demonstrating this similarity.

The application of biological systems, living organisms, or their components to develop and manufacture products, such as large-molecule APIs like proteins and peptides.

The chemical modification of a substance by a living organism or enzyme. In manufacturing, it can refer to a specific enzymatic step in a synthesis.

A study design approach used in stability testing that reduces the total number of samples tested. Bracketing tests only the extremes of certain design factors (e.g., strength), while matrixing involves testing a selected subset of all possible sample combinations at specific time points.

The unformulated Active Pharmaceutical Ingredient before it is mixed with excipients to create the final drug product.

The German Federal Institute for Drugs and Medical Devices, which acts as the regulatory authority for pharmaceuticals in Germany.

This term refers to conditions or These are technologies that operate at extremely cold temperatures, usually below -150 °C. They are commonly used to turn gases into liquids for storage, preserve biological samples like cells and tissues, and support advanced scientific work in areas such as superconductivity and quantum computing, where maintaining ultra-low temperatures is essential.

A systematic cGMP process for investigating and resolving quality deviations by addressing the root cause (corrective action) and implementing changes to prevent recurrence (preventive action).

A service provider to the pharmaceutical industry offering a comprehensive suite of services from process development and clinical trial manufacturing to commercial production.

A set of stringent, legally enforceable regulations governing the design, monitoring, and control of manufacturing processes to ensure products are consistently safe, pure, and effective.

A service provider specializing in the manufacturing of pharmaceutical products or components on a contract basis for other companies.

The former name for China's primary regulatory body for pharmaceuticals, now known as the National Medical Products Administration (NMPA).

The scientific and engineering activities focused on devising and optimizing chemical processes for the safe, efficient, and scalable production of active pharmaceutical ingredients and their intermediates, typically moving from laboratory to commercial scale.

An API molecule that is non-superimposable on its mirror image, requiring manufacturing processes that can produce the correct single isomer.

The documented process that proves a cleaning procedure consistently removes residual active ingredients, intermediates, and cleaning agents from equipment down to predetermined, safe levels.

A class of chemical reactions that are rapid, efficient, and high-yielding, often used for creating complex molecules or bioconjugates.

The cGMP-grade API produced for use in human clinical trials, manufactured under strict regulatory oversight to ensure patient safety.

The section of a regulatory submission containing all detailed information on an API's manufacturing process, quality control tests, specifications, and stability.

Mexico's regulatory body responsible for overseeing pharmaceuticals and health products.

The management of the supply chain for temperature-sensitive products, ensuring they are stored and transported within a specified temperature range to maintain quality and stability.

The large-scale, routine production of an API after it has received regulatory approval for public sale.

The state of being in full accordance with all applicable regulations, guidelines, and internal procedures.

Peptides that present significant synthetic and purification challenges due to their length, unusual amino acid residues, post-translational modifications, or cyclic structures.

A specially designed and engineered area used for the safe handling and manufacturing of highly potent substances, utilizing equipment like isolators to protect employees and prevent cross-contamination.

An advanced purification technique, particularly for complex mixtures, that operates continuously rather than in batches, offering increased efficiency, higher purity, and reduced solvent consumption.

An advanced manufacturing method where API is produced in an uninterrupted flow, as opposed to traditional batch-by-batch production, to enhance efficiency and consistency.

This is a business approach where a company delegates the production of its goods to an external manufacturer that specializes in that process.

This refers to a substance whose production, handling, and usage are strictly governed by legal regulations due to its risk of misuse or dependency, often requiring authorized permissions and secure management.

An integrated service provider offering comprehensive support across the entire drug development lifecycle, from early-stage research and development to clinical and commercial manufacturing.

The operational parameters within a manufacturing process (e.g., temperature, pressure) that must be tightly controlled to ensure the consistent production of a product with the desired quality attributes.

The physical, chemical, or biological properties of a substance that must be controlled within a defined limit to ensure the desired product quality.

A service organization that supports an industry with research-based activities, such as preclinical studies, clinical trial management, and bioanalysis.

A critical purification and isolation step in which a solid, crystalline material is formed from a solution to achieve desired physical properties like particle size, purity, and polymorphic form.

Tailored chemical synthesis and process development solutions provided by a contract organization to meet specific client requirements, often for novel compounds, complex intermediates, or specialized reactions.

The specialized synthesis of peptides on a contract basis, tailored to a client's specific sequence and quality requirements.

The chemical process of creating a specific peptide sequence that is not commercially available off-the-shelf.

Peptides where the amino acid chain forms a ring structure, often conferring enhanced stability, bioavailability, or specific receptor binding properties compared to linear peptides.

A chemical reaction that introduces a cyano (-CN) group into a molecule. Cyanated compounds are important intermediates in pharmaceutical synthesis and can be found in various drug structures.

A powerful statistical methodology used during process development to efficiently study the relationships between multiple process parameters and the resulting product quality attributes.

Molecules where one or more hydrogen atoms (protium) have been replaced by deuterium, an isotope of hydrogen that has one proton and one neutron in its nucleus. Due to deuterium's heavier mass, deuterated molecules exhibit subtle but measurable differences in their physical and chemical properties, such as vibrational frequencies, reaction rates, and nuclear magnetic resonance (NMR) spectra. They are often used in research as tracers or for spectroscopic analysis.

 The maintenance and assurance of data accuracy, completeness, and consistency over its entire lifecycle, a critical cGMP principle.

An impurity resulting from a chemical change in a substance over time or due to reaction with its environment (e.g., light, heat).

The entire multi-stage process of bringing a new drug to market, from discovery and preclinical research through clinical trials, regulatory approval, and post-market monitoring.

The early-stage process of identifying and screening new compounds to find potential candidates for new drugs.

A confidential submission made to a regulatory authority containing comprehensive details about the manufacturing of an API. A company can grant permission for partners to reference this file in their own regulatory filings.

The final, finished dosage form (e.g., tablet, injectable) that contains the drug substance (API) along with other inactive ingredients (excipients).

A regulatory term synonymous with Active Pharmaceutical Ingredient (API); the unformulated bulk material that is physically and chemically active in the final drug product.

An annual report submitted to regulatory authorities during the clinical trial phase, providing a comprehensive analysis of the safety information collected for a drug under investigation.

A risk mitigation strategy where a company qualifies two distinct suppliers to manufacture the same product, ensuring continuity of supply.

The initial stages of drug development, including preclinical and Phase I/II clinical trials, which require process development, scale-up, and cGMP manufacturing of API.

A global platform that provides sustainability ratings and performance improvement tools for global supply chains. They assess companies' environmental, social, and ethical performance, including labor practices, fair business practices, and sustainable procurement. Businesses use Ecovadis ratings to evaluate their suppliers' sustainability performance, drive improvements, and foster more responsible and transparent supply chains.

Mechanisms that allow patients with serious diseases to gain access to promising investigational drugs before they are fully approved.

An organization that publishes the European Pharmacopoeia and grants Certificates of Suitability (CEPs), which demonstrate compliance with European quality standards for APIs.

A comprehensive program that manages all aspects of environmental protection, occupational health, and workplace safety.

Trace amounts of metallic impurities (e.g., lead, palladium) that can be present in a product and must be controlled according to ICH Q3D guidelines to ensure safety.

The European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.

A measure of the presence of one enantiomer (a specific stereoisomer) in a chiral substance compared to its mirror image.

Peptides synthesized or modified using enzymatic reactions, often offering higher specificity, milder reaction conditions, and greener manufacturing routes compared to traditional chemical synthesis.

The use of enzymes as catalysts to perform highly specific chemical transformations in the synthesis of pharmaceuticals, often leading to more efficient and environmentally friendly processes.

A critical quality control test, particularly for sterile products, used to detect and quantify bacterial endotoxins. The Limulus Amebocyte Lysate (LAL) test is the standard method.

A cGMP program, especially critical in aseptic processing, that involves systematically sampling and testing the manufacturing environment (air, surfaces) to prevent contamination.

The use of enzymes to accelerate chemical reactions, often leading to greater specificity, milder reaction conditions, and less waste.

The European equivalent of the US Drug Master File; a confidential document submitted to European health authorities to support a client's Marketing Authorization Application.

The collection of rules and regulations governing medicinal products in the European Union. Volume 4 contains the EU's Good Manufacturing Practice (GMP) guidelines.

An inactive substance that serves as the vehicle or medium for an active ingredient in a final drug product.

Chemical compounds that can migrate from manufacturing equipment or container closure systems into a product. Studies are required to identify and quantify these potential contaminants.

Studies performed to identify chemical compounds that could potentially be extracted from manufacturing equipment or packaging materials under harsh conditions.

FTIR is a fast and non-invasive method used to identify and confirm materials by analyzing how they absorb infrared radiation.

The final manufacturing stage for injectable drugs, involving the aseptic filling of the drug product into its primary container (e.g., vials or syringes) and then sealing it.

The documented process providing a high degree of assurance that a specific filtration step will consistently remove particles or microorganisms from a fluid stream without negatively impacting the product. 

The final, marketed form of a drug product, such as a tablet, capsule, injectable solution, or cream, which is ready for administration to a patient.

A systematic, proactive risk assessment tool used to identify potential failures within a process and analyze their potential consequences on product quality and safety.

A study where a substance is intentionally exposed to stress conditions (e.g., heat, light, acid) to understand its degradation pathways and develop stability-indicating analytical methods.

The process of designing and creating a stable, safe, and effective drug product by combining the Active Pharmaceutical Ingredient (API) with appropriate inactive ingredients (excipients).

The process of refining a drug formulation to improve its characteristics, such as stability, bioavailability, or patient compliance.

A process used to remove water from a heat-sensitive substance by freezing it and then reducing the pressure to allow the frozen water to sublimate directly from a solid to a gas.

Active Pharmaceutical Ingredients that are the therapeutically equivalent, off-patent versions of branded drugs.

An Active Pharmaceutical Ingredient for use in a generic drug product, which is bioequivalent to a previously approved branded drug.

A framework of standards used to confirm that automated systems in the pharmaceutical sector perform reliably and comply with regulatory expectations.

This method is mainly used to separate and study substances that easily turn into gases, making it vital for procedures like checking for leftover solvents in samples.

The direct manipulation of an organism's genes using biotechnology, often to develop high-yield cell lines for producing biologic APIs.

A class of DNA-reactive impurities that have the potential to cause genetic mutations and are considered a significant safety risk, requiring stringent process controls and sensitive analytical methods.

A synonym for cGMP; the set of quality system regulations that must be followed to ensure every batch of product is safe, pure, and effective.

A formal inspection of a company's facilities, quality systems, and procedures conducted by a client or a regulatory agency to verify compliance with Good Manufacturing Practices.

The manufacturing of peptides under strict cGMP conditions, making them suitable for use as APIs in clinical trials and commercial drug products.

The ongoing training program that ensures all employees understand their roles and responsibilities related to cGMP and are kept up to date on regulatory requirements.

Established engineering methods and standards applied throughout a project lifecycle to deliver appropriate and cost-effective solutions in the design and maintenance of facilities and equipment.

A process that causes fine powders to bind together to form larger, more uniform particles called granules, often to improve handling or processing properties.

The analysis of the physical properties of granules, such as size distribution, density, and flowability, important for APIs intended for solid dosage forms.

An approach to chemical process design that aims to reduce or eliminate the use and generation of hazardous substances, improving sustainability and efficiency.

A general term for quality guidelines and regulations in the life sciences, including cGMP, Good Laboratory Practice (GLP), and Good Documentation Practice (GDP).

Peptides manufactured and purified to a very high level of quality, often >98%, making them suitable for use as APIs in pharmaceutical applications.

An API that is therapeutically effective at a very low dose, requiring specialized handling and containment facilities to ensure worker safety and prevent cross-contamination.

A systematic process of identifying potential hazards in a manufacturing process and evaluating their potential to cause harm.

A major class of organic molecules that form the structural core of many APIs.

A specialized area designed with engineering controls (like isolators and single-pass air systems) to safely handle and manufacture High Potency APIs (HPAPIs).

A process used to create solid dispersions of an API within a polymer matrix, often to enhance the solubility of poorly soluble drugs.

A primary analytical technique used to separate, identify, and quantify the components in a mixture, making it essential for determining the purity and potency of an API.

A manufacturing strategy combining elements of both Solid Phase Peptide Synthesis (SPPS) and Solution Phase Peptide Synthesis to efficiently produce long or complex peptides.

A chemical reaction, typically involving hydrogen gas and a metal catalyst, that is a common and critical transformation step in many API synthesis routes.

The property of being "water-loving" or readily dissolving in water, a key physicochemical property of an API.

A purification technique used to separate proteins based on their hydrophobicity.

An application submitted to the U.S. FDA to request permission to start clinical trials in humans, which requires comprehensive CMC data on the API.

A set of internationally harmonized technical guidelines for the pharmaceutical industry on topics such as quality, stability, and impurities. Adherence ensures products are acceptable in major global markets.

Any component present in a substance that is not the desired chemical entity, including process-related by-products and degradation products.

The process of separating and purifying a specific impurity from an API matrix so that its chemical structure can be determined.

A detailed characterization of all known and unknown impurities present in an API, established during process development to ensure batch-to-batch consistency.

Tests and checks performed at critical points during a manufacturing process to monitor and ensure it remains within defined limits, guaranteeing final product quality.

The development and application of new technologies, chemistries, and manufacturing processes to improve efficiency, quality, and sustainability.

A service model where a single contract organization provides a broad range of services covering the entire drug development and manufacturing lifecycle, from API to final drug product.

Intangible assets such as novel synthetic routes, crystallization processes, or analytical methods that are protected by law.

A document submitted to European regulatory authorities containing the CMC, preclinical, and clinical data for a drug used in a clinical trial.

Certification indicating that an organization's management system (e.g., for quality or environmental management) meets the requirements of a standard developed by the International Organization for Standardization.

A raw material or intermediate that is incorporated as a significant structural fragment into an API. Its introduction into the process typically marks the start of full cGMP controls.

Previously known as the Korea Food & Drug Administration (KFDA), this agency is now called the Ministry of Food and Drug Safety (MFDS) and serves as South Korea’s main regulatory body for food and pharmaceuticals

A dedicated lab setup designed to produce materials in kilogram quantities, acting as a key transitional stage between small-scale synthesis in research labs and larger-scale production in pilot plants

The manufacturing of material in quantities typically ranging from one to one hundred kilograms, usually performed in a Kilo Lab or Pilot Plant.

A measure of the solubility of a substance under non-equilibrium conditions, which can be more relevant to certain pharmaceutical processes than thermodynamic solubility.

The systematic process of capturing, sharing, and using the collective knowledge within an organization, critical for successful technology transfer and continuous improvement.

Peptides consisting of more than 100 amino acid residues, whose synthesis and purification present significant technical challenges and require specialized expertise.

A software-based system used in a quality control lab to manage and track samples, experiments, results, and data, ensuring data integrity and operational efficiency.

A term for biopharmaceuticals, such as proteins and monoclonal antibodies, which have a complex, high molecular weight structure, contrasting with chemically synthesized small molecules.

Peptides produced in quantities typically ranging from kilograms to hundreds of kilograms, requiring optimized synthetic routes, efficient purification methods, and specialized manufacturing equipment.

A powerful analytical technique that combines the separation capabilities of HPLC with the detection power of mass spectrometry, used for identifying and quantifying trace-level impurities.

A stage in drug discovery where a promising compound (a "lead") is chemically modified to improve its properties, often requiring complex synthesis of various analogues for testing.

The strategy for managing a product across its entire lifespan, from launch to patent expiry, which can include process optimization and development of next-generation versions.

Also known as freeze-drying, this is a dehydration process used for heat-sensitive substances that involves freezing the material and then reducing the pressure to allow the frozen water to sublimate.

The cGMP-required process of providing documented evidence that a specific analytical method is suitable for its intended purpose by proving it is accurate, precise, specific, and reliable.

The process of progressively increasing the production volume of a substance, moving from small lab batches to pilot plant and finally to commercial scale, while ensuring quality is maintained.

A formal, approved set of instructions for manufacturing a specific product, containing all necessary information to ensure consistency from batch to batch.

A study performed to ensure that materials used in manufacturing equipment and container closure systems do not negatively interact with the product.

The interdisciplinary field studying the properties of matter and their application. In API manufacturing, it applies to understanding and controlling solid-state properties like polymorphism.

The process of reducing the average particle size of a solid substance down to the micrometer range, often to improve its solubility and bioavailability.

A type of impurity that has the potential to cause DNA mutations, a subset of genotoxic impurities subject to extremely strict control strategies.

An API containing a molecule that has not been previously approved by a regulatory authority as a drug substance.

The formal submission to the U.S. FDA requesting approval to market a new drug, containing comprehensive CMC data on the API.

A class of potent, potentially carcinogenic impurities that can form in certain products, requiring rigorous risk assessments and testing to ensure their absence at unacceptable levels.

The production of substances under less stringent controls than cGMP, intended for purposes such as early-stage research or material for toxicology studies.

Studies conducted in vitro or in animals to gather safety and efficacy data for a drug candidate before it is tested in humans.

The construction of organic compounds via chemical reactions, the fundamental activity of small-molecule API manufacturing.

A system that groups chemicals into bands based on their potency and potential health effects (e.g., OEB 1-5), helping to determine the required level of containment and handling precautions.

The concentration of a substance in the workplace air to which a worker can be exposed without adverse health effects, which dictates the level of containment required.

The process of chemically synthesizing short sequences of DNA or RNA, which are increasingly used as therapeutic agents (e.g., antisense oligonucleotides, siRNAs) or in diagnostics.

A peptide made up of a small number (typically 2 to 20) of amino acid residues.

The formal, documented investigation process initiated following an Out of Specification (OOS) result to determine its cause and implement appropriate corrective and preventive actions.

A management philosophy that emphasizes continuous improvement across all aspects of an organization's operations to achieve greater efficiency and quality.

The documented verification that a piece of equipment or a system operates as intended throughout its specified operating ranges, a key part of the overall validation process.

A drug developed to treat a rare disease or condition, often involving smaller production volumes and accelerated regulatory pathways.

Any test result that falls outside the pre-defined acceptance criteria established in a product's specification, triggering a mandatory and thorough investigation.

Molecules, particularly proteins or peptides, that have been modified by the attachment of polyethylene glycol (PEG) chains. Pegylation often improves the drug's pharmacokinetic properties, such as increasing its half-life, reducing immunogenicity, and enhancing solubility.

The science of designing and controlling the size, shape, and surface properties of particles to achieve a desired performance characteristic, such as improved solubility or flowability.

A structured approach used in manufacturing that relies on real-time tracking of key quality indicators to guide design, control, and decision-making—ultimately enhancing product consistency and reliability.

A patient-centered supply chain approach often used in clinical research and personalized treatments, focusing on adaptability, direct-to-patient delivery, and ensuring timely access to required medications.

A Contract Development and Manufacturing Organization with specialized expertise and equipment for the synthesis, purification, and analysis of peptide APIs.

The process of using a range of analytical techniques to confirm the identity, structure, sequence, and purity of a peptide API.

A novel peptide molecule that has not been previously approved as a drug substance by a regulatory authority, representing a new therapeutic innovation.

The critical step in peptide manufacturing where the desired peptide is isolated from a complex mixture of impurities, often using techniques like preparative HPLC.

The chemical process of linking amino acids together to form a peptide, the core manufacturing activity of a peptide-focused API producer.

An official publication, issued by a regulatory body, that provides standards and specifications for APIs, excipients, and drug products (e.g., USP, Ph. Eur.).

An intermediate-scale manufacturing facility used to test a process before scaling it up to commercial size, also used to produce material for later-stage clinical trials.

The primary regulatory authority for pharmaceuticals and medical devices in Japan.

A study conducted to identify all possible crystalline forms (polymorphs) of a substance, which is critical because different polymorphs can have different physical properties.

Any changes made to the manufacturing process, specifications, or facility of a product after it has received regulatory approval, which must be reported to health authorities.

The ongoing monitoring of a drug's safety after it has been approved and launched.

Studies conducted in vitro or in animals to gather safety and efficacy data for a drug candidate before it is tested in humans.

A phase of research and development where the physicochemical properties of an Active Pharmaceutical Ingredient are characterized to guide the development of a stable and effective dosage form.

The branch of chemistry that focuses on developing and optimizing chemical synthetic routes to make them suitable for large-scale, safe, and efficient manufacturing.

A core activity focusing on designing a manufacturing process that is robust, scalable, safe, and economically viable, resulting in a well-understood process that consistently delivers high-quality product.

This department within an organization, often in manufacturing or pharmaceuticals, is responsible for thoroughly examining deviations, anomalies, or failures in established processes. Their goal is to identify the root causes of these issues, implement corrective and preventive actions, and ultimately improve the efficiency, quality, and safety of the processes. Think of them as the detectives of the operational world, figuring out why something went wrong and how to make sure it doesn't happen again.

Work done to refine an existing manufacturing process to improve its yield, reduce costs, decrease cycle time, or enhance its environmental profile.

A systematic evaluation of the potential hazards associated with a chemical manufacturing process, aimed at ensuring the safety of personnel, the facility, and the environment.

The cGMP-required activity of providing documented evidence that a manufacturing process, when operated within its established parameters, consistently produces a product meeting its predetermined specifications.

The process of managing the entire lifecycle of a product from inception, through engineering design and manufacture, to service and disposal.

The measure of the degree to which a substance is free from unwanted impurities. Achieving and demonstrating a high level of purity is a primary goal of API manufacturing.

A systematic, science- and risk-based approach to development that focuses on deeply understanding the relationship between process inputs and product attributes to build quality into the product from the start.

In the European Union, a designated expert who is legally responsible for certifying that each batch of product has been manufactured and tested in accordance with EU GMP and regulatory approvals.

The overarching quality management function responsible for ensuring that all systems, procedures, and processes comply with cGMP regulations, including documentation review and audit management.

The hands-on, laboratory-based function responsible for testing raw materials, intermediates, and final products against their established specifications to ensure they meet quality standards.

Data used to monitor the effectiveness of a pharmaceutical quality system and drive continuous improvement, such as batch success rates and deviation reports.

The status of materials that are set aside and unavailable for use until they have been tested by a quality control department and formally released.

The specific sequence of chemical reactions and steps used to convert starting materials into the final API.

Any substance used in the production of a final product. Suppliers must be qualified and incoming materials tested to ensure they meet required quality standards.

The process of systematically adjusting reaction conditions (like temperature and concentration) to maximize the yield and purity of the desired product while minimizing impurities.

The function that acts as the interface with global health authorities, providing strategic regulatory advice and preparing regulatory documentation like DMFs.

The process of gathering and analyzing publicly available regulatory information and trends to anticipate changes in the regulatory landscape.

Trace amounts of organic volatile chemicals that remain in a final product after manufacturing is complete and must be controlled to be below safe limits defined in ICH Q3C.

A systematic process used to identify, analyze, and evaluate potential risks to product quality (as per ICH Q9) or to process safety, with results used to guide development and control strategies.

A term used to define the starting point for the cGMP-controlled portion of an API synthesis, often used interchangeably with Key Starting Material (KSM).

A technique where a peptide is built sequentially while one end is attached to a solid polymer bead (resin), facilitating purification at each step.

The process of adapting a chemical process from a laboratory setting to a larger scale for manufacturing in a pilot plant or commercial facility, while maintaining quality.

The process of using stability study data to establish the time period during which a substance is expected to remain within its approved specification under defined storage conditions.

The property of a substance (solute) to dissolve in a solvent to form a homogeneous solution, a key physicochemical property for APIs.

The study of the synthesis, structure, and physical properties of solid materials, crucial for understanding and controlling polymorphism, crystallinity, and other properties that can impact a drug's performance.

A traditional method of peptide synthesis where reactions are carried out in a solution, often used for large-scale production of shorter peptides.

The process of capturing and purifying used solvents from a manufacturing process so they can be reused, a key part of green chemistry and cost-reduction initiatives.

A detailed, written instruction that describes how to perform a specific, routine operational task. Adherence to SOPs is fundamental to cGMP compliance and consistency.

A detailed list of tests, analytical procedures, and acceptance criteria that a product must meet to be considered acceptable for its intended use.

A formal program to evaluate how the quality of a substance changes over time under defined storage conditions, used to establish a retest period or shelf life.

The production of substances under conditions that prevent microbial contamination, resulting in a product that is free from viable microorganisms.

The management of the flow of goods and services, including the movement and storage of raw materials, in-process inventory, and finished products from producer to client.

The formal, documented process of transferring a manufacturing process and its associated knowledge and analytical methods from one entity to another (e.g., from a client to a contractor).

A planning tool used in drug development that outlines the desired characteristics of a final drug product, guiding development activities.

The regulatory authority for therapeutic goods in Australia.

A safety assessment performed to understand the thermal properties of a chemical reaction, such as its potential for a dangerous, runaway thermal event.

The length of time it takes from a product being conceived until it is available for sale.

A common laboratory method of quantitative chemical analysis used to determine the concentration of an identified analyte.

The scientific study of the adverse effects that chemicals can have on living organisms. Material for toxicology studies is required to assess the safety of a new drug candidate.

In a business partnership, refers to open, honest, and proactive communication regarding project progress, challenges, and results.

A Drug Master File submitted to the U.S. Food and Drug Administration (USFDA)

The UN Global Compact is a voluntary initiative based on CEO commitments to implement universal sustainability principles and to take steps to support UN goals. It encourages businesses worldwide to adopt sustainable and socially responsible policies and to report on their implementation. The UNGC focuses on ten universally accepted principles in the areas of human rights, labor, environment, and anti-corruption, aiming to mobilize a global movement of sustainable companies and stakeholders.

A basic step in a larger chemical or manufacturing process, such as a reaction, distillation, filtration, or crystallization.

In biotechnology, the initial stage of the process where cells or microorganisms are grown in bioreactors to produce the desired biologic API.

A document that specifies what the user requires from a piece of equipment or a system, serving as the first step in the validation process for new equipment.

The U.S. Food and Drug Administration, the primary regulatory agency for pharmaceuticals in the United States.

A non-profit organization that sets public standards for the quality, purity, strength, and identity of medicines. A product may be required to meet the specifications in a USP monograph.

The combined publication of the USP and the National Formulary, providing standards for APIs, excipients, and other healthcare products.

The formal process by which a company evaluates and approves its suppliers of critical raw materials, components, and services to ensure they meet required quality standards.

The active component of a vaccine that elicits an immune response, such as a recombinant protein or mRNA.

The cGMP-required process of providing documented evidence that a specific process, piece of equipment, system, or method consistently produces a result meeting predetermined acceptance criteria.

A high-level document that describes an organization's overall validation strategy, policies, and approach to maintaining a validated state for facilities, equipment, and processes.

The process of accurately filling sterile vials with a liquid or lyophilized product, typically performed under aseptic conditions.

Studies performed for biologic APIs produced in cell culture to demonstrate that the manufacturing and purification process is effective at removing or inactivating viruses.

The process of visually examining a final product for any particulate matter or defects. For sterile products, this is a critical inspection step.

Organic compounds that easily evaporate at room temperature and must be carefully managed to meet environmental standards due to their potential impact on air quality

Impurities that have a high vapor pressure and can be analyzed using techniques like headspace gas chromatography, including residual solvents.

A type of laboratory environment where chemicals, biological materials, or other substances are handled in liquid form, often requiring the use of water, solvents, and various reagents. It is characterized by the presence of sinks, fume hoods, safety showers, and specialized equipment for liquid handling, mixing, heating, and cooling. This contrasts with a "dry lab" which might focus on computational work or analysis without direct handling of liquids.

The comprehensive system used for the collection, treatment, and disposal of all chemical and biological waste generated during manufacturing, in accordance with environmental regulations.

The highest grade of purified water, used in the production of sterile products, which must be generated and stored in a validated system.

A process of creating granules by adding a liquid binder to a powder mixture to improve its handling or processing properties.

An agency of the United Nations concerned with international public health. Its Prequalification of Medicines Programme is important for suppliers of drugs for global health initiatives.

A reference standard of a substance that is prepared and qualified in-house against a primary, official pharmacopoeial standard, used for routine quality control testing.

The use of technology to automate manual, repetitive tasks in a laboratory or manufacturing setting to improve efficiency and reduce the risk of human error.